Federal Project Grant Award Summary

The Johns Hopkins University received a $120,437 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026 through August 31, 2029. The project, titled "Chemotherapy Induction Regimen for Lineage Switch AML," supports investigator-initiated biomedical research addressing Service Member health and battlefield medicine priorities. The award will be performed at Johns Hopkins University's Baltimore, Maryland facility, where the institution will conduct clinical and translational research activities aligned with the DHA's strategic mission to transform healthcare for Service Members through innovative medical solutions.

This three-year project represents one of the DHA's Project Grant awards, which comprise approximately 88 percent of the Military Medical Research and Development program portfolio. Johns Hopkins University brings substantial research infrastructure and federal contracting experience to the initiative, having previously secured significant funding from the Defense Health Agency and other federal agencies for biomedical research spanning cancer, infectious disease, and clinical investigation domains. The award falls within the typical award range of $100,000 to $20 million supported by the Military Medical Research and Development program for projects with average performance periods of three to four years.